newsfilter
← Latest News
GlobeNewswire·

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates